and MATSUMOTO, K. Combination Therapy o f Esophageal Carcinoma with Radiation and Bleomycin. Tohoku J. exp. Med., 1981, 134 (4), 417-424--The concurrent combination therapy of radiation and Bleomycin was performed in a total of 175 cases of esophageal carcinoma. In 107 (63%) cases of them, in which the scheduled curative treatment was completed, yearly survival rates were 60% in one, 30% in two, 20% in three and 7% in five years. The local recurrence was noted in 60% and remote metastases were observed in 38% of them. These results were intimately correlated to tumor advancement and cancer type. From the results, it was concluded that this combination therapy should be valuable to prolong the life of a cancer patient, improving one to three year survival rates, and that the curable indications for this treatment should be T1 MO and T2 MO with tumorous or some ulcerous types of carcinoma, radiation therapy; esophagea carcinoma; BleomycinRecently, combinations of radiation and surgery have improved the treatment results of esophageal carcinoma, while the indications for surgery are greatly limited by the advancement of tumor, the tumor location, complications at advanced age, etc. Radiation therapy is the one and only curative treatment for the cases in which esophagectomy is not indicated. But, the treatment results in radiation therapy of esophageal carcinoma are generally poor and five-year survival rate is less than 10%, because of dose limiting problems that will restrict the role of radiation therapy and specific characteristics of this carcinoma, such as the invasion of vital structures, diffuse infiltration of the submucosa, skip lesions and early lymph node metastases.To augment the radiation effect on primary lesion and lymph node metastases within the irradiation field, we have been trying the concurrent combination therapy of radiation and Bleomycin for esophageal carcinoma. In this treatment, chemotherapeutic effect of Bleomycin alone may be also expected on the subclinical invasions and/or metastases in the outside of irradiation field.In this study, to evaluate this combination therapy of esophageal carcinoma, yearly survival rates and the status of local recurrence and metastases are analyzed and discussed in relation to some clinical factors.

The concurrent combination therapy of radiation and chemotherapy was performed in a total of 134 cases of stomach cancer. Radiation response of tumor was remarkable in 35 (37%) of 95 cases, irradiated more than 5,000 rad. Yearly survival rates in 81 cases, in which the scheduled curative treatment was completed, were 63% in one, 31% in two, 21% in three, 17% in four and 13% in five years. These rates were intimately correlated to tumor size and cancer type. However, this combination therapy accompanied some fatal complications in a few percent. From the results, it was concluded that this combination therapy should be valuable to prolong the life of patients with gastric cancer, and that the curable indications for this treatment should be T1-T3: MO cases with radio-responsive tumor.radiotherapy; chemotherapy; gastric carcinoma Gastric carcinoma is the most frequent one in Japan. In the treatment of gastric cancer the curable possibility is only expected by curative resection of the stomach. However, locally unresectable and medically inoperable cases are not rare, in spite of a remarkable progress of the diagnostic method for gastric carcinoma. For such cases in which gastrectomy is not indicated, chemotherapy is generally employed to prolong the life of a cancer patient, but its effect is greatly limited.On the other hand, the radiation therapy of gastric cancer has been thought to be inadequate, because of relative radioresistance of gastric carcinoma and of the limited radiotolerance of adjacent organs, such as the small intestine, large bowel and kidneys.Since 1967, we have been trying the concurrent combination therapy of gastric carcinoma with 6 MV x-ray and some anticancer drugs to potentiate the radiation effect on the malignant lesions within the irradiation field. In this therapy, it is expected that chemotherapy alone may be also effective on the subclinical invasions and/or apparent remote metastases in the outside of the irradiation field. In this study, radiation response of tumor, yearly survival rates and

No abstract